PRTK News and Press, Paratek Pharmaceuticals Inc. From 03/14/22

Paratek Pharmaceuticals, Inc. (PRTK) Q4 2021 Earnings Conference Call March 14, 2022 08:30 ET Company Participants Sarah Higgins - Vice President, Finance, Controller and Principal Accounting Officer Evan Loh - Chief Executive Officer Adam Woodrow - President and Chief Commercial Officer Rand...

Image source: The Motley Fool. Paratek Pharmaceuticals (NASDAQ: PRTK) Q4 2021 Earnings Call Mar 14, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: Paratek Pharmaceuticals (PRTK) Q4 2021 Earnings Call Transcript

Paratek Pharmaceuticals press release (NASDAQ:PRTK): FY GAAP EPS of -$1.22 misses by $0.31. Revenue of $130.16M (+177.4% Y/Y) misses by $3.57M. For further details see: Paratek Pharmaceuticals GAAP EPS of -$1.22 misses by $0.31, revenue of $130.16M misses by $3.57M

-- NUZYRA ® (omadacycline) Generated Net U.S. Sales of $106.1 Million Comprised of $68.2 Million from the Core Commercial Business, a 76% increase over Prior Year, and $37.9 Million from the Initial Procurement of NUZYRA under the BARDA Bioshield Contract -- Approva...

ADAP, AVEO, BLDP, CORR, GOL, JAGX, LUNA, MTBC, PEI, PRTK For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Monday's open

BOSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. announced today the publication of data from an investigator-initiated study evaluating the activity of NUZYRA® (omadacycline) in a dynamic hollow fiber model of Mycobacterium avium complex (MAC) pulmonary inf...

BOSTON, March 02, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Monday, March 14 at 8:30 a.m. EST to provide a corporate update and report its financial results for fourth quarter ...

BeiGene began trading on the Shanghai STAR Board as the last step in its $3.5 billion IPO. The company is now listed in the US, Hong Kong and Shanghai. Jinan Qilu Pharma entered a $300 million agreement to acquire greater China rights to an RNAi therapy for hepatitis B developed by Ar...

BOSTON, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company’s partner in China, Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), received approval from the National Medical Products Administration (NMPA) of China of NUZYRA ...

Calliditas Therapeutics (NASDAQ:CALT) +38% on FDA approval for kidney disease therapy. Kaixin Auto (NASDAQ:KXIN) +27% on a partnership agreement with Bujia for 10k new energy trucks. Biomerica (NASDAQ:BMRA) +18% preliminary second quarter revenue increase of approxima...